SEQUA.BR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:57):

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure...

Stats
今日成交量	45 796.00
平均成交量	104 221
市值	42.04M
EPS	€0 ( 2023-02-09 )
下一个收益日期	( €0 ) 2024-05-23
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.050
ATR14	€0.0110 (0.79%)

Sequana Medical NV 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sequana Medical NV 财务报表

Annual	2023
营收:	€712 000
毛利润:	€-4.15M (-583.43 %)
EPS:	€-1.220

FY	2023
营收:	€712 000
毛利润:	€-4.15M (-583.43 %)
EPS:	€-1.220

FY	2022
营收:	€922 687
毛利润:	€718 090 (77.83 %)
EPS:	€-1.350

FY	2021
营收:	€370 500
毛利润:	€293 837 (79.31 %)
EPS:	€-0.751

Financial Reports:

No articles found.

Sequana Medical NV

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.